Trial Profile

Clinical study of Natalizumab for the treatment of Relapsing Remitting Multiple Sclerosis (RRMS).

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 06 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Natalizumab (Primary) ; Natalizumab (Primary)
Indications Multiple sclerosis
Focus Therapeutic Use

Most Recent Events

06 Jun 2024 New trial record
18 Apr 2024 Results(n=17) assessing Immunomonitoring of Intravenous and Subcutaneous Natalizumab presented at the 76th Annual Meeting of the American Academy of Neurology 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com